Current status of pancreatic cancer with oligometastasis.

BACKGROUND: Pancreatic cancer is the seventh leading cause of death worldwide, with ductal adenocarcinoma as the most frequent neoplasm. Half of the patients who are diagnosed have metastases at the time of diagnosis. OBJECTIVE: A review of the treatment of resectable pancreatic adenocarcinoma with oligometastatic disease was carried out in order to present an overview of the existing evidence. METHOD: A bibliographic search was carried in PubMed/Medline, Clinical Key and Index Medicus vhith MESH terms, from the year 1993 to 2022. RESULTS: Patients with liver or lung metastases due to pancreatic ductal adenocarcinoma who undergo surgery and chemotherapy have a longer survival in carefully selected patients. CONCLUSIONS: The evidence regarding surgery in patients with pancreatic ductal adenocarcinoma and oligometastasis is limited and further randomized controlled trials are needed for both scenarios. As well as established criteria that help the selection of patients who can receive this type of treatment.

ANTECEDENTES: El cáncer pancreático es la séptima causa de muerte en el mundo, siendo el adenocarcinoma ductal del páncreas la neoplasia más frecuente. La mitad de los pacientes que son diagnosticados presentan metástasis al momento del diagnóstico. OBJETIVO: Se realizó una revisión sobre el tratamiento del adenocarcinoma pancreático resecable con enfermedad oligometastásica con el fin de presentar un panorama sobre la evidencia existente. MÉTODO: Se realizó una búsqueda bibliográfica en PubMed/Medline, Clinical Key e Index Medicus con términos MESH desde 1993 hasta 2022. RESULTADOS: Los pacientes con metástasis hepáticas o pulmonares por adenocarcinoma ductal de páncreas que son sometidos a cirugía y quimioterapia tienen una mayor sobrevida en casos cuidadosamente seleccionados. CONCLUSIONES: La evidencia respecto a la cirugía en pacientes con adenocarcinoma ductal de páncreas y oligometástasis es limitada y se necesitan ensayos controlados aleatorizados adicionales para ambos escenarios, así como criterios bien establecidos que ayuden a la selección de los pacientes que pueden recibir este tipo de tratamiento.

Intramedullary pancreatic adenocarcinoma metastasis: The first case in literature / Metástasis de adenocarcinoma de páncreas intramedular: primer caso en la literatura

Background Pancreatic cancer is a common gastrointestinal malignancy, and is often associated with a poor prognosis. Although liver is generally seen as a distant metastasis point, it has been shown that it can metastasize to any organ, especially the gastrointestinal tract, and approximately 0.3% of metastases are observed in spinal cord. Case description We report a 36-year-old woman with a prior history of pancreatic adenocarcinoma who presented to us with a thoracic intramedullary lesion and recent onset of neurological deficits. She underwent surgery with histological confirmation of a diagnosis of metastatic adenocarcinoma. Conclusion To our knowledge there is no prior report of pure intramedullary spinal cord metastasis from a pancreatic adenocarcinoma in the literature. We report the present patient in view of the rarity of intramedullary spinal cord metastasis and its clinical significance. Although intramedullary metastases are rare, they should be investigated in every patient with malignancy and progressive neurological deficit. While its general prognosis is poor regardless of the type of treatment, early diagnosis and treatment is important in terms of quality of life and survival (AU)

Antecedentes El cáncer de páncreas es una neoplasia maligna gastrointestinal común y, a menudo, se asocia con un mal pronóstico. Aunque el hígado generalmente se ve como un punto de metástasis distante, se ha demostrado que puede hacer metástasis a cualquier órgano, especialmente al tracto gastrointestinal, y aproximadamente el 0,3% de las metástasis se observan en la médula espinal. Descripción del caso Presentamos una mujer de 36 años con antecedentes de adenocarcinoma de páncreas que se presentó con una lesión intramedular torácica y de reciente aparición de déficits neurológicos. Fue intervenida quirúrgicamente con confirmación histológica de diagnóstico de adenocarcinoma metastásico. Conclusión Hasta donde sabemos, no existe en la literatura ningún informe previo de metástasis intramedular pura de la médula espinal de un adenocarcinoma pancreático. Presentamos el presente paciente en vista de la rareza de la metástasis intramedular de la médula espinal y su importancia clínica. Aunque las metástasis intramedulares son raras, deben investigarse en todo paciente con neoplasia maligna y déficit neurológico progresivo. Si bien su pronóstico general es malo independientemente del tipo de tratamiento, el diagnóstico y el tratamiento precoces son importantes en términos de calidad de vida y supervivencia (AU)

Intramedullary pancreatic adenocarcinoma metastasis: The first case in literature.

BACKGROUND: Pancreatic cancer is a common gastrointestinal malignancy, and is often associated with a poor prognosis. Although liver is generally seen as a distant metastasis point, it has been shown that it can metastasize to any organ, especially the gastrointestinal tract, and approximately 0.3% of metastases are observed in spinal cord. CASE DESCRIPTION: We report a 36-year-old woman with a prior history of pancreatic adenocarcinoma who presented to us with a thoracic intramedullary lesion and recent onset of neurological deficits. She underwent surgery with histological confirmation of a diagnosis of metastatic adenocarcinoma. CONCLUSION: To our knowledge there is no prior report of pure intramedullary spinal cord metastasis from a pancreatic adenocarcinoma in the literature. We report the present patient in view of the rarity of intramedullary spinal cord metastasis and its clinical significance. Although intramedullary metastases are rare, they should be investigated in every patient with malignancy and progressive neurological deficit. While its general prognosis is poor regardless of the type of treatment, early diagnosis and treatment is important in terms of quality of life and survival.

¿Qué aporta la imagen tridimensional preoperatoria en la cirugía pancreática compleja? / What does preoperative three-dimensional image contribute to complex pancreatic surgery?

La posibilidad de modelización de imágenes diagnósticas en tres dimensiones (3D) en cirugía pancreática es una novedad que nos aporta múltiples ventajas. Una mejor visualización de las estructuras nos permite una planificación de la técnica quirúrgica más precisa y nos facilita la realización de la cirugía en casos complejos. Presentamos el caso de un paciente diagnosticado de un adenocarcinoma de cabeza de páncreas borderline para ilustrar las ventajas de la modelización 3D en cirugía pancreática compleja. La ayuda de la tecnología 3D nos permitió planificar de manera óptima la intervención facilitando la resección quirúrgica. El uso de esta herramienta podría traducirse en: menor tiempo operatorio, menores complicaciones intraoperatorias o un aumento de las resecciones R0. La usabilidad del programa utilizado en nuestro caso, ágil e intuitivo, fue una ventaja añadida. (AU)

The possibility of modelling diagnostic images in three dimensions (3D) in pancreatic surgery is a novelty that provides us multiple advantages. A better visualization of the structures allows us a more accurate planning of the surgical technique and makes it easier the surgery in complex cases. We present the case study of a borderline pancreatic head adenocarcinoma patient to illustrate the advantages of 3D modelling in complex pancreatic surgery. The help of 3D technology allowed us to optimally plan the intervention and facilitate surgical resection. The use of this tool could translate into: shorter operative time, fewer intraoperative complications or an increase in R0 resections. The usability of the program used in our case, agile and intuitive, was an added advantage. (AU)

Psoas muscle mass, nutritional status, inflammation, and their relationship with prognosis in patients with pancreatic adenocarcinoma / Masa del músculo psoas, estado nutricional, inflamación y su relación con el pronóstico en pacientes con adenocarcinoma de páncreas

Introduction: some factors have been shown to be associated with survival in patients with pancreatic adenocarcinoma. Recently, some studies suggested that malnutrition, muscle mass, and inflammation might have an effect on survival in patients with pancreatic malignancy. Objectives: to investigate the association between psoas muscle mass, inflammation, nutritional status at the time of diagnosis, and survival in patients with pancreatic adenocarcinoma. Methods: this retrospective study included 219 patients diagnosed with pancreatic carcinoma. The nutritional status, inflammation, and psoas muscle mass of the patients at the time of diagnosis were evaluated. Nutritional status was assessed using the Prognostic Nutritional Index (PNI). Leucocyte count and neutrophil/lymphocyte ratio (NLR) were used for inflammation assessment. Psoas muscle mass was calculated by using abdominal computed tomography images of the patients. Results: the mean age of patients (80 female and 139 male) was 66.6 ± 11.7 years. According to the PNI results, 155 patients had a normal nutritional status (70 %), whereas 64 patients were malnourished (30 %). The survival of the patients with normal nutritional status was significantly longer than that of those who were malnourished (p < 0.001). There was no significant relationship between psoas muscle area, leucocyte count, NLR, and survival time. Conclusion: the survival of pancreatic adenocarcinoma patients with malnutrition at the time of diagnosis was significantly shorter than for patients without malnutrition. (AU)

Introducción:se ha demostrado que algunos factores se asocian a la supervivencia en los pacientes con adenocarcinoma de páncreas. Recientemente, algunos estudios sugirieron que la desnutrición, la masa muscular y la inflamación podrían afectar a la supervivencia de los pacientes con neoplasias malignas pancreáticas.Objetivo: investigar la asociación entre masa muscular del psoas, inflamación, estado nutricional en el momento del diagnóstico y supervivencia en pacientes con adenocarcinoma de páncreas. Métodos: este estudio retrospectivo incluyó a 219 pacientes diagnosticados de carcinoma de páncreas. Se evaluaron el estado nutricional, la inflamación y la masa del músculo psoas de los pacientes en el momento del diagnóstico. El estado nutricional de los pacientes se evaluó con el Índice Nutricional Pronóstico (PNI). El recuento de leucocitos y el cociente de neutrófilos/linfocitos (NLR) se emplearon para la evaluación de la inflamación. La masa del músculo psoas se calculó utilizando las imágenes de tomografía computarizada abdominal de los pacientes. Resultados: la edad media de los pacientes (80 mujeres y 139 hombres) fue de 66,6 ± 11,7 años. Según los resultados del PNI, 155 pacientes tenían un estado nutricional normal (70 %) mientras que 64 pacientes estaban desnutridos (30 %). La supervivencia de los pacientes con estado nutricional normal fue significativamente mayor que la de los pacientes desnutridos (p < 0,001). No hubo ninguna relación significativa entre el área del músculo psoas, el recuento de leucocitos, el NLR y el tiempo de supervivencia. Conclusión: la supervivencia de los pacientes con adenocarcinoma de páncreas con desnutrición en el momento del diagnóstico fue significativamente menor que la de los pacientes sin desnutrición. (AU)

What does preoperative three-dimensional image contribute to complex pancreatic surgery?

The possibility of modelling diagnostic images in three dimensions (3D) in pancreatic surgery is a novelty that provides us multiple advantages. A better visualization of the structures allows us a more accurate planning of the surgical technique and makes it easier the surgery in complex cases. We present the case study of a borderline pancreatic head adenocarcinoma patient to illustrate the advantages of 3D modelling in complex pancreatic surgery. The help of 3D technology allowed us to optimally plan the intervention and facilitate surgical resection. The use of this tool could translate into: shorter operative time, fewer intraoperative complications or an increase in R0 resections. The usability of the program used in our case, agile and intuitive, was an added advantage.

Psoas muscle mass, nutritional status, inflammation, and their relationship with prognosis in patients with pancreatic adenocarcinoma.

INTRODUCTION: Introduction: some factors have been shown to be associated with survival in patients with pancreatic adenocarcinoma. Recently, some studies suggested that malnutrition, muscle mass, and inflammation might have an effect on survival in patients with pancreatic malignancy. Objectives: to investigate the association between psoas muscle mass, inflammation, nutritional status at the time of diagnosis, and survival in patients with pancreatic adenocarcinoma. Methods: this retrospective study included 219 patients diagnosed with pancreatic carcinoma. The nutritional status, inflammation, and psoas muscle mass of the patients at the time of diagnosis were evaluated. Nutritional status was assessed using the Prognostic Nutritional Index (PNI). Leucocyte count and neutrophil/lymphocyte ratio (NLR) were used for inflammation assessment. Psoas muscle mass was calculated by using abdominal computed tomography images of the patients. Results: the mean age of patients (80 female and 139 male) was 66.6 ± 11.7 years. According to the PNI results, 155 patients had a normal nutritional status (70 %), whereas 64 patients were malnourished (30 %). The survival of the patients with normal nutritional status was significantly longer than that of those who were malnourished (p < 0.001). There was no significant relationship between psoas muscle area, leucocyte count, NLR, and survival time. Conclusion: the survival of pancreatic adenocarcinoma patients with malnutrition at the time of diagnosis was significantly shorter than for patients without malnutrition.

INTRODUCCIÓN: Introducción: se ha demostrado que algunos factores se asocian a la supervivencia en los pacientes con adenocarcinoma de páncreas. Recientemente, algunos estudios sugirieron que la desnutrición, la masa muscular y la inflamación podrían afectar a la supervivencia de los pacientes con neoplasias malignas pancreáticas. Objetivo: investigar la asociación entre masa muscular del psoas, inflamación, estado nutricional en el momento del diagnóstico y supervivencia en pacientes con adenocarcinoma de páncreas. Métodos: este estudio retrospectivo incluyó a 219 pacientes diagnosticados de carcinoma de páncreas. Se evaluaron el estado nutricional, la inflamación y la masa del músculo psoas de los pacientes en el momento del diagnóstico. El estado nutricional de los pacientes se evaluó con el Índice Nutricional Pronóstico (PNI). El recuento de leucocitos y el cociente de neutrófilos/linfocitos (NLR) se emplearon para la evaluación de la inflamación. La masa del músculo psoas se calculó utilizando las imágenes de tomografía computarizada abdominal de los pacientes. Resultados: la edad media de los pacientes (80 mujeres y 139 hombres) fue de 66,6 ± 11,7 años. Según los resultados del PNI, 155 pacientes tenían un estado nutricional normal (70 %) mientras que 64 pacientes estaban desnutridos (30 %). La supervivencia de los pacientes con estado nutricional normal fue significativamente mayor que la de los pacientes desnutridos (p < 0,001). No hubo ninguna relación significativa entre el área del músculo psoas, el recuento de leucocitos, el NLR y el tiempo de supervivencia. Conclusión: la supervivencia de los pacientes con adenocarcinoma de páncreas con desnutrición en el momento del diagnóstico fue significativamente menor que la de los pacientes sin desnutrición.

Intramedullary pancreatic adenocarcinoma metastasis: The first case in literature.

BACKGROUND: Pancreatic cancer is a common gastrointestinal malignancy, and is often associated with a poor prognosis. Although liver is generally seen as a distant metastasis point, it has been shown that it can metastasize to any organ, especially the gastrointestinal tract, and approximately 0.3% of metastases are observed in spinal cord. CASE DESCRIPTION: We report a 36-year-old woman with a prior history of pancreatic adenocarcinoma who presented to us with a thoracic intramedullary lesion and recent onset of neurological deficits. She underwent surgery with histological confirmation of a diagnosis of metastatic adenocarcinoma. CONCLUSION: To our knowledge there is no prior report of pure intramedullary spinal cord metastasis from a pancreatic adenocarcinoma in the literature. We report the present patient in view of the rarity of intramedullary spinal cord metastasis and its clinical significance. Although intramedullary metastases are rare, they should be investigated in every patient with malignancy and progressive neurological deficit. While its general prognosis is poor regardless of the type of treatment, early diagnosis and treatment is important in terms of quality of life and survival.

What does preoperative three-dimensional image contribute to complex pancreatic surgery? / ¿Qué aporta la imagen tridimensional preoperatoria en la cirugía pancreática compleja?

The possibility of modelling diagnostic images in three dimensions (3D) in pancreatic surgery is a novelty that provides us multiple advantages. A better visualization of the structures allows us a more accurate planning of the surgical technique and makes it easier the surgery in complex cases. We present the case study of a borderline pancreatic head adenocarcinoma patient to illustrate the advantages of 3D modelling in complex pancreatic surgery. The help of 3D technology allowed us to optimally plan the intervention and facilitate surgical resection. The use of this tool could translate into: shorter operative time, fewer intraoperative complications or an increase in R0 resections. The usability of the program used in our case, agile and intuitive, was an added advantage.

A expressão e relevância da proteína IMPACT no Adenocarcinoma de Pâncreas / Expression and relevance of IMPACT protein in Pancreatic Adenocarcinoma

Um dos principais pontos de controle da tradução de mRNAs ocorre através da fosforilação da subunidade alfa do fator de início de tradução eIF2 (eIF2α), o que leva à inibição da síntese geral de proteínas. GCN2 é uma das quinases de eIF2α que responde à carência de aminoácidos e radiação UV, fosforilando eIF2α e inibindo a tradução geral. Sua atividade depende da união com a proteína GCN1. A proteína IMPACT também interage com GCN1, competindo pela ligação GCN1-GCN2, inibindo a atividade de GCN2 e estimulando a tradução. Através de pesquisas em bancos de dados utilizando o cBioPortal, observamos que em adenocarcinomas de pâncreas, existem alterações nos genes que codificam IMPACT, GCN1 e GCN2 em uma porcentagem significativa de casos. No Brasil, este tumor é responsável por cerca de 2% de todos os tipos de câncer diagnosticados e por 4% do total de mortes por câncer. Devido à natureza agressiva da doença e ao diagnóstico tardio, a maioria dos pacientes apresenta o câncer localmente avançado ou metastático, possuindo uma alta taxa de mortalidade e sobrevida de 5 anos menor que 7%. Portanto, desvendar mecanismos moleculares associados a este tumor é de extrema importância para o desenvolvimento de novas abordagens terapêuticas. Utilizando um modelo celular de adenocarcinoma de pâncreas, nocaute para IMPACT, realizamos ensaios funcionais. eIF2 foi mais fosforilado pelas linhagens nocautes na avaliação por estresse a UV, mas não para privação de leucina. Além disso, células nocautes também apresentaram menor capacidade de formar colônias independentemente de ancoragem, e menos formação tumoral nos ensaios em vivo, além de apresentarem menor capacidade de formar e manter estruturas 3D avaliadas no ensaio de esferoides e adesão. A partir da avaliação dos Tissue Micro Arrays (TMAs), tumores primários apresentaram maior quantidade de IMPACT quando comparados com tumores metastáticos e tecido normal. Interessantemente, tanto no TMA quanto nas linhagens celulares foram observados grânulos de IMPACT tanto no núcleo quanto no citoplasma e associados a proteínas características de grânulos de estresse e proteínas do nucléolo. Diante dos resultados encontrados, podemos concluir que a proteína IMPACT pode ter atuação no ciclo celular além de fazer parte de grânulos de estresse. Além disso, levanta-se a hipótese que pode atuar em dois momentos na progressão tumoral: um primeiro momento onde a superexpressão favoreceria a sobrevivência do tumor e um segundo momento onde a diminuição de IMPACT facilitaria a metástase. Portanto o estudo dessa proteína pode melhorar o entendimento não só dos mecanismos envolvidos no desenvolvimento e progressão do Adenocarcinoma de Pâncreas, mas também de processos biológicos relacionados com outros tumores e até mesmo outras doenças.

Is the involvement of the hepatic artery lymph node a poor prognostic factor in pancreatic adenocarcinoma? / ¿Es realmente la afectación del ganglio de la arteria hepática un factor de mal pronóstico en el adenocarcinoma de páncreas?

INTRODUCTION: The aim of this study is to analyze the impact of hepatic artery lymph node (HALN) involvement on the survival of patients undergoing pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA). METHODS: A single-center retrospective study analyzing patients who underwent PD for PA. Patients were included if, during PD, the HALN was submitted for pathologic evaluation. Patients were stratified by node status: PPLN- (peripancreatic lymph node)/HALN-, PPLN+/HALN- and PPLN+/HALN+. Survival analysis was estimated by the Kaplan-Meier method, and Cox regression was used for risk factors analyses. RESULTS: Out of the 118 patients who underwent PD for PA, HALN status was analyzed in 64 patients. The median follow-up was 20months (r: 1-159months). HALN and PPLN were negative in 12patients (PPLN-/HALN-, 19%), PPLN was positive and HALN negative in 40patients (PPLN+/HALN-, 62%), PPLN and HALN were positive in 12 patients (PPLN+/HALN+, 19%) and PPLN was negative and HALN positive in 0 patients (PPLN-/HALN+, 0%). The overall 1, 3 and 5-year survival rates were statistically better in the PPLN-/HALN- group (82%, 72%, 54%) than in the PPLN+/HALN- group (68%, 29%, 21%) and the PPLN+/HALN+ group (72%, 9%, 9%, respectively) (P=.001 vs P=.007). The 1, 3 and 5-year probabilities of cumulative recurrence were also statistically better in the PPLN-/HALN- group (18%, 46%, 55%) than in the PPLN+/HALN- group (57%, 80%, 89%) and the PPLN+/HALN+ group (46%, 91%, 100%, respectively) (P=.006 vs P=.021). In the multivariate model, the main risk factor for overall survival and recurrence was lymphatic invasion, regardless of HALN status. CONCLUSIONS: In pancreatic adenocarcinoma patients with lymph node disease, survival after PD is comparable regardless of HALN status.

Nimotuzumab y gemcitabina en el tratamiento del cáncer de páncreas y metástasis esplénica / Nimotuzumabe e gencitabina no tratamento do câncer de pâncreas e metástases esplênicas / Nimotuzumab and gemcitabine in the treatment of pancreatic cancer and splenic metastases

Se presentó un paciente masculino de 69 años con una colestasis extrahepática, pérdida de peso, astenia y anorexia, antecedentes de pancreatitis crónica, diabetes mellitus e hipertensión arterial, el cual fue diagnosticado con adenocarcinoma de páncreas con metástasis esplénica. Se le realizó colecistoyeyunostomía con yeyunoyeyunostomía por ser irresecable el tumor. Fue incluido en el ensayo clínico IIC RDEC166 y tratado con nimotuzumab y gemcitabina. En los estudios evolutivos no se apreciaron las imágenes metastásicas que se observaron antes del tratamiento lo que presupone la utilidad de estos fármacos para el control de éstas. No se encontraron referentes sobre el tema en la literatura nacional e internacional consultadas(AU)

A 69-year-old male patient presented with extrahepatic cholestasis, weight loss, asthenia and anorexia, a history of chronic pancreatitis, diabetes mellitus and arterial hypertension, who was diagnosed with adenocarcinoma of the pancreas with splenic metastases. A cholecystojejunostomy was performed with jejunum jejunostomy because the tumor was unresectable. It was included in the IIC RDEC166 clinical trial and treated with nimotuzumab and gemcitabine. In the evolutionary studies the metastatic images that were observed before the treatment were not appreciated, which presupposes the usefulness of these drugs for their control. No references on the subject were found in the national and international literature consulted(AU)

Paciente do sexo masculino, 69 anos, apresentou colestase extrahepática, perda de peso, astenia e anorexia, história de pancreatite crônica, diabetes mellitus e hipertensão arterial, diagnosticada com adenocarcinoma do pâncreas com metástases esplênicas. Uma colecistojejunostomia foi realizada com jejuno jejunostomia porque o tumor era irressecável. Foi incluído no ensaio clínico IIC RD-EC166 e tratado com nimotuzumab e gencitabina. Nos estudos evolutivos, as imagens metastáticas observadas antes do tratamento não foram apreciadas, o que pressupõe a utilidade desses medicamentos para seu controle. Não foram encontradas referências sobre o assunto na literatura nacional e internacional consultada(AU)

Eficácia da punção aspirativa por agulha fina percutânea guiada por ultrassonografia no diagnóstico de lesões pancreáticas / Efficacy of percutaneous fine needle aspiration guided By in the diagnosis of pancreatic lesions

Correlacionar os achados citológicos obtidos por punção aspirativa por agulha fina ecoguiada com o seguimento clínico ou resultado histopatológico dos pacientes. Estudo transversal observacional com análise de 32 prontuários de pacientes com lesões pancreáticas submetidos à PAAF, sendo consideradas as variáveis: idade; sexo; topografia da lesão; diagnóstico citopatológico; resultado do exame histopatológico e de congelação por punção. Foi calculada a sensibilidade do método em diagnosticar malignidade e a sensibilidade, especificidade, VPP, VPN e acurácia para o diagnóstico de adenocarcinoma. A média de idade dos pacientes foi 64,9 anos com predomínio do sexo feminino; a cabeça do pâncreas foi a topografia mais acometida pelas lesões (64%); o diagnóstico mais freqüente foi de adenocarcinoma (78%). O método apresentou sensibilidade de 93% para malignidade e 92% para adenocarcinoma. A PAAF, na presente casuística, se mostrou rápida, segura e eficaz, tendo alta correlação com o exame histopatológico ou evolução clínica.

To correlate the cytological findings obtained by ultrasonically guided by fine needle aspiration and with clinical follow-up of patients. An observational cross-sectional study was done, on which 32 records of patients with pancreatic lesions underwent FNA were analyzed, considering the following variables: age, sex, topography of the lesion, diagnosis, descriptive diagnosis, result of histopathological and freezing by puncture. Were calculated the sensitivity of the method in diagnosing malignancy and the sensitivity, specificity, PPV, NPV and accuracy for diagnosing adenocarcinoma. The average age of patients was 64,9 years with a predominated of female, the head of the pancreas was most affected by the topography of lesions (64%), the most common diagnosis was adenocarcinoma (78%). The method had sensitivity for malignancy of 93% and 92% for adenocarcinoma. FNA, in this series, proved to be fast, safe and effective having high correlation with histopathology and clinical outcome in this study.

Sensibilidad y especificidad del CA 19-9 para el diagnóstico de neoplasias pancreatobiliares en pacientes con ictericia de origen obstructivo / Sensitivity and specificity of CA-19-9 for the diagnosis of pancreatobiliary neoplasms in patients with obstructive-origin jaundice

Objetivo: Describir el comportamiento biológico del CA 19-9 en colestasis para determinar su utilidad para el diagnóstico de cáncer pancreatobiliar en pacientes con ictericia de origen obstructivo. Sede: Hospital General de México, O.D. Diseño: Prospectivo, longitudinal y comparativo. Análisis estadístico: prueba t y Kolmogorov-Smirnov para muestras independientes; prueba de valor diagnóstico (sensibilidad, especificidad y valor global). Se realizó análisis con curvas ROC para identificar sensibilidad y especificidad con los diferentes puntos de corte. Pacientes y métodos: Se incluyeron 54 pacientes con diagnóstico de ictericia de origen obstructivo. Se dividieron en dos grupos de acuerdo al diagnóstico final, enfermedad maligna vs enfermedad benigna. Se realizó determinación sérica de CA 19-9 al ingreso y al resolver la colestasis y se correlacionaron los niveles con el diagnóstico final. Resultados: En pacientes ictéricos, con un punto de corte de 60 U/mL para distinguir entre enfermedad maligna y benigna, el CA 19-9 tiene una sensibilidad de 80% y una especificidad de 90%. Una vez resuelta la colestasis con punto de corte de 39 U/mL se obtiene una sensibilidad de 71% con una especificidad de 96%. La normalización del marcador después del drenaje biliar es altamente sugerente de patología benigna. La persistencia de niveles elevados (mayores de 60 U/mL) es altamente sugerente de malignidad con una sensibilidad de 58% y especificidad de 100%. Conclusiones: La colestasis sí modifica la sensibilidad y especificidad del CA 19-9 para el diagnóstico de neoplasias malignas pancreatobiliares, por lo que en presencia de ictericia de origen obstructivo el punto de corte de 60 U/mL ofrece una sensibilidad de 80% con una especificidad de 90% para distinguir entre enfermedad benigna y maligna. Una vez resuelta la colestasis, la persistencia de niveles elevados es altamente sugerente de malignidad.

Objective: To describe the biological behavior of the tumor marker CA 19-9 in cholestasis to determine its usefulness for the diagnosis of pancreatobiliary cancer in patients with obstructive-origin jaundice. Sede: General Hospital of Mexico, third level health care center. Mexico City. Design: Prospective, longitudinal, and comparative study. Statistical analysis: T and Kolmogorov Smirnov tests for independent samples; diagnostic value test (sensitivity, specificity, and global value). Analysis with ROC curves was performed to identify sensitivity and specificity at the different cutting points. Patients and methods: We included 54 patients with a diagnosis of obstructive-origin jaundice. They were divided in two groups according to the final diagnosis, malignant disease vs. benign disease. Serum CA 19-9 was determined at admittance and once cholestasis had been resolved, and the levels were correlated with the final diagnosis. Results: In jaundice patients, with a cut point of 60 U/mL to distinguish between malignant and benign disease, the CA 19-9 marker has a sensitivity of 80% and a specificity of 90%. Once cholestasis had been resolved with a cut point of 39 U/mL, sensitivity was of 71% with a 96% specificity. Normalization of the marker after bile drainage is highly suggestive of benign pathology. The persistence of high levels (higher than 60 U/mL) is highly suggestive of malignancy with a sensitivity of 58% and specificity of 100%. Conclusions: Cholestasis does modify the sensitivity and specificity of the CA 19-9 marker for the diagnosis of pancreatobiliary malignant neoplasms; therefore, in the presence of obstructive-origin jaundice, the 60 U/mL cut point offers a sensitivity of 80% with a specificity of 90% to be able to distinguish between malignant and benign disease. Once cholestasis has been resolved, persistence of high levels is highly suggestive of malignancy.